vTv Therapeutics (NASDAQ:VTVT) Earns Buy Rating from Analysts at Roth Mkm

Roth Mkm assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report published on Thursday morning, MarketBeat.com reports. The firm issued a buy rating and a $58.00 target price on the biotechnology company’s stock.

A number of other research firms also recently commented on VTVT. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a report on Saturday, December 27th. TD Cowen began coverage on vTv Therapeutics in a research note on Monday, January 5th. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 price objective (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Finally, BTIG Research began coverage on vTv Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $40.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $53.00.

vTv Therapeutics Price Performance

Shares of VTVT stock opened at $34.11 on Thursday. vTv Therapeutics has a 1-year low of $13.96 and a 1-year high of $44.00. The business’s fifty day moving average price is $34.03 and its 200 day moving average price is $24.65. The firm has a market capitalization of $134.39 million, a PE ratio of -10.27 and a beta of 0.48.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Institutional Investors Weigh In On vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP grew its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the period. Baker BROS. Advisors LP owned 3.77% of vTv Therapeutics worth $3,463,000 at the end of the most recent reporting period. 17.51% of the stock is owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.